The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Tulmimetostat Monotherapy Phase 1: Frequency of Dose-limiting toxicities (DLTs)
Timeframe: DLTs assessed during Cycle 1 (cycle = 28 days)
Tulmimetostat Monotherapy Phase 2: Overall response rate (ORR)
Timeframe: Up to 30 months
Cohort M8 Part 1: Frequency of Dose-limiting toxicities (DLTs)
Timeframe: DLTs assessed during Cycle 1 (cycle = 28 days)
Cohort M8 Part 2: Overall response rate (ORR)
Timeframe: Up to 30 months